This reengineered HPV vaccine trains T cells to hunt down cancer
Northwestern researchers repositioned an HPV protein fragment on a DNA-based spherical nucleic acid vaccine and dramatically amplified CD8 T-cell responses in animal models, with one design slowing tumor growth and extending survival despite identical vaccine components.
Why it mattersNorthwestern's DNA nanovaccine for HPV increased CD8 T cells, prompting prioritization of T-cell-focused candidates.